VIENNA, Va., May 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(Amex: CVM) announces that the results of a long-term survival study of
cancer patients treated with CEL-SCI's drug Multikine(R) will be presented
at a scientific conference during May 2006. Specifically, the data relates
to head & neck cancer patients treated with Multikine in a Phase II
clinical trial concluded over 3.5 years ago.
Data from the follow-up study indicate that Multikine treatment
resulted in a substantial increase in the survival of head & neck cancer
patients. In addition, Multikine treatment also improved the local regional
control of the patients' tumors. Improved local regional control of the
tumor is considered by many surgeons and oncologists to be an important
measurement of the success of a head & neck cancer therapy. Both survival
and local regional control of the tumor are stated endpoints in CEL-SCI's
planned Phase III clinical trial.
The Phase II study, which used the same Multikine treatment protocol as
proposed for the Phase III trial, included advanced primary head & neck
cancer patients who were scheduled for their first cancer treatment. The
Multikine treatment was administered for three weeks prior to the standard
treatment for head & neck cancer, surgery or surgery plus
radiation/chemotherapy. Results from this study were published in a leading
cancer publication, the Journal of Clinical Oncology (Timar et al, JCO,
23(15): May 2005).
Head & neck cancer is an aggressive cancer that affects about 500,000
people per annum worldwide. About 92% of those cases are outside of the
U.S., and about two thirds of all cases present with advanced disease.
Multikine is a patented immunotherapeutic agent consisting of a mixture
of naturally occurring cytokines, including interleukins, interferons,
chemokines and colony-stimulating factors, currently being developed for
treatment of cancer.
The Company's lead product Multikine is cleared to enter global Phase
III clinical trials in advanced primary head and neck cancer patients (by
Canadian Regulators). CEL-SCI's other products, which are currently in
pre-clinical stage and are funded with U.S. government support, have shown
protection against a number of diseases in animal tests and are being
tested against diseases associated with bio-defense and avian flu.
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland.
When used in this report, the words "intends," "believes,"
"anticipated" and "expects" and similar expressions are intended to
identify forward-looking statements. Such statements are subject to risks
and uncertainties which could cause actual results to differ materially
from those projected. Factors that could cause or contribute to such
differences include, an inability to duplicate the clinical results
demonstrated in clinical studies, timely development of any potential
products that can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the Company's
potential products, inability to raise the necessary capital and the risk
factors set forth from time to time in CEL-SCI Corporation's SEC filings,
including but not limited to its report on Form 10- K for the year ended
September 30, 2005. The Company undertakes no obligation to publicly
release the result of any revision to these forward-looking statements
which may be made to reflect the events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
Stockholders Contact: Gavin de Windt of
CEL-SCI Corporation, +1-703-506-9460; or Institutional Investors,
Brokers and Analysts Contact: Michael Lucci, +1-248-723-3330, for
CEL-SCI Corporation
|
